P. L. Collins and J. A. Melero, Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years, Virus Res, vol.162, pp.80-99, 2011.

P. S. Mcnamara and R. L. Smyth, The pathogenesis of respiratory syncytial virus disease in childhood, Br Med Bull, vol.61, pp.13-28, 2002.

M. F. Delgado, S. Coviello, A. C. Monsalvo, G. A. Melendi, Z. Hernandez et al., Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease, Nat Med, vol.15, pp.34-41, 2009.

J. A. Beeler and K. Van-wyke-coelingh, Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus : Effect of Mutation upon Fusion Function, J Virol, vol.63, pp.2941-2950, 1989.

P. L. Hervé, C. Deloizy, D. Descamps, M. Rameix-welti, J. Fix et al.,

, RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine, Nanomedicine, vol.13, issue.2

. A-c-c-e-p-t-e-d-m-a-n-u-s-c-r-i-p-t,

, Mol Biol, vol.409, pp.853-66, 2011.

B. E. Correia, J. T. Bates, R. J. Loomis, G. Baneyx, C. Carrico et al., Proof of principle for epitope-focused vaccine design, Nature, vol.507, pp.201-207, 2014.

D. Higgins, C. Trujillo, and C. Keech, Advances in RSV vaccine research and development -A global agenda, Vaccine, vol.34, pp.2870-2875, 2016.

P. Piedra, A. Jewell, S. Cron, R. Atmar, and W. Glezen, Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies, Vaccine, vol.21, pp.3479-3482, 2003.

G. Taylor, L. H. Thomas, S. G. Wyld, J. Furze, P. Sopp et al., Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves, J Virol, vol.69, pp.6658-64, 1995.

E. Guzman and G. Taylor, Immunology of bovine respiratory syncytial virus in calves, Mol Immunol, vol.66, pp.48-56, 2015.

T. Tran, N. Castagné, D. Bhella, P. F. Varela, J. Bernard et al., The nine Cterminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer, J Gen Virol, vol.88, pp.196-206, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00167652

R. G. Tawar, S. Duquerroy, C. Vonrhein, P. F. Varela, L. Damier-piolle et al., Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus, Science, vol.326, pp.1279-83, 2009.
URL : https://hal.archives-ouvertes.fr/pasteur-00457523

X. Roux, C. Dubuquoy, G. Durand, T. Tran-tolla, N. Castagné et al., Sub-Version postprint Comment citer ce document

P. L. Hervé, C. Deloizy, D. Descamps, M. Rameix-welti, J. Fix et al.,

, RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine, Nanomedicine, vol.13, issue.2

A. Pierantoni, M. L. Esposito, V. Ammendola, F. Napolitano, F. Grazioli et al.,

, Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates, Mol Ther -Methods Clin Dev, vol.2, p.15018, 2015.

J. H. Schickli, D. C. Whitacre, R. S. Tang, J. Kaur, H. Lawlor et al., Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge, J Clin Invest, vol.125, pp.1637-1647, 2015.

R. H. Florese, T. Demberg, P. Xiao, L. Kuller, K. Larsen et al., Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines, J Immunol, vol.182, pp.3718-3745, 2009.

A. J. Hessell, L. Hangartner, M. Hunter, C. Havenith, F. J. Beurskens et al., Fc receptor but not complement binding is important in antibody protection against HIV, Nature, vol.449, pp.101-105, 2007.

A. Jegerlehner, N. Schmitz, T. Storni, and M. F. Bachmann, Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity, J Immunol, vol.172, pp.5598-605, 2004.

K. El-bakkouri, F. Descamps, M. De-filette, A. Smet, E. Festjens et al., Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection, J Immunol, vol.186, pp.1022-1053, 2011.

J. S. Mclellan, M. Chen, S. Leung, K. W. Graepel, X. Du et al., Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody, Science, vol.340, pp.1113-1117, 2013.

, Version postprint Comment citer ce document

P. L. Hervé, C. Deloizy, D. Descamps, M. Rameix-welti, J. Fix et al.,

, RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine, Nanomedicine, vol.13, issue.2